Katarína Rašlová
Basal insulin analogues are used to minimize unpredictable processes of NPH insulin namely hypoglycaemia. Insulin detemir is a basal insulin analogue that provides effective therapeutic option for patients with type 1 and type 2 diabetes. With respect to glycaemic control, no significant differences were found in HbA1c levels when compared with NPH and insulin glargine. It has been demonstrated that insulin detemir has significantly lower variability of glycaemia than NPH insulin and insulin glargin. Recent pharmacodynamic studies have shown that detemir can be used once-daily in many patients with diabetes. It is comparable with insulin glargine in significantly reducing rates of all types of hypoglycaemia, however, it provides another clinical benefit of no or less weight gain than NPH insulin or insulin glargine.